Protective immune response against Toxoplasma gondii elicited by a recombinant DNA vaccine with a novel genetic adjuvant

Vaccine

Volumn 30, Issue 10, 2012, Pages 1800-1806

  Zhou, Huaiyu ^a   Min, Juan ^a   Zhao, Qunli ^a   Gu, Qinmin ^a   Cong, Hua ^a   Li, Ying ^a   He, Shenyi ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

DNA vaccine; Genetic adjuvant; GRA2; SAG1; Toxoplasma gondii

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 4; RECOMBINANT DNA VACCINE SAG1 GRA2; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FUSION GENE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO GENE TRANSFER; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; SURVIVAL TIME; TH1 CELL; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CELLS, CULTURED; FEMALE; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; PLASMIDS; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; TH1 CELLS; TOXOPLASMA; TOXOPLASMOSIS; VACCINES, DNA;

EID: 84862829834     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.004     Document Type: Article

References (53)

1. Dubey J.P. The history of Toxoplasma gondii-the first 100 years. J Eukaryot Microbiol 2008, 55(6):467-475.
2. Montoya J.G., Liesenfeld O. Toxoplasmosis. Lancet 2004, 363(9425):1965-1976.
3. Weiss L.M., Dubey J.P. Toxoplasmosis: a history of clinical observations. Int J Parasitol 2009, 39(8):895-901.
4. Petersen E. Toxoplasmosis. Semin Fetal Neonal Med 2007, 12(3):214-223.
5. Buxton D., Maley S.W., Wright S.E., Rodger S., Bartley P., Innes E.A. Toxoplasma gondii and ovine toxoplasmosis: new aspects of an old story. Vet Parasitol 2007, 149(1-2):25-28.
6. Cenci-Goga B.T., Rossitto P.V., Sechi P., McCrindle C.M., Cullor J.S. Toxoplasma in animals, food, and humans: an old parasite of new concern. Foodborne Pathog Dis 2011, 8(7):751-762.
7. Jongert E., Roberts C.W., Gargano N., Förster-Waldl E., Petersen E. Vaccines against Toxoplasma gondii: challenges and opportunities. Mem Inst Oswaldo Cruz 2009, 104(2):252-266.
8. Buxton D., Thomson K., Maley S., Wright S., Bos H.J. Vaccination of sheep with a live incomplete strain (S48) of Toxoplasma gondii and their immunity to challenge when pregnant. Vet Rec 1991, 129(5):89-93.
9. Buxton D., Innes E.A. A commercial vaccine for ovine toxoplasmosis. Parasitology 1995, 110(Suppl.):S11-S16.
10. Innes E.A., Bartley P.M., Maley S., Katzer F., Buxton D. Veterinary vaccines against Toxoplasma gondii. Mem Inst Oswaldo Cruz 2009, 104(2):246-251.
11. Kur J., Holec-Gasior L., Hiszczyńska-Sawicka E. Current status of toxoplasmosis vaccine development. Expert Rev Vaccines 2009, 8(6):791-808.
12. Dubey J.P., Lindsay D.S., Speer C.A. Structures of Toxoplasma gondii tachyzoites: bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev 1998, 11(2):267-299.
13. Alexander J., Jebbari H., Bluethmann H., Satoskar A., Roberts C.W. Immunological control of Toxoplasma gondii and appropriate vaccine design. Curr Top Microbiol Immunol 1996, 219:183-195.
14. Khan I.A., Ely K.H., Kasper L.H. A purified parasite antigen (p30) mediates CD8+ T cell immunity against fatal Toxoplasma gondii infection in mice. J Immunol 1991, 147(10):3501-3506.
15. Biemans R., Grégoire D., Haumont M., Bosseloir A., Garcia L., Jacquet A., et al. The conformation of purified Toxoplasma gondii SAG1 antigen, secreted from engineered Pichia pastoris, is adequate for serorecognition and cell proliferation. J Biotechnol 1998, 66(2-3):137-146.
16. Petersen E., Nielsen H.V., Christiansen L., Spenter J. Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii. Vaccine 1998, 16(13):1283-1289.
17. Rolland D., Raymond F., Gauthier M., Fournier C., Charrier J.P., Jolivet M., et al. Strategies for improving production and purification of a recombinant protein: rP30 of Toxoplasma gondii expressed in the yeast Schizosaccharomyces pombe. J Chromatogr B: Analyt Technol Biomed Life Sci 2008, 861(2):186-195.
18. Darcy F., Maes P., Gras-Masse H., Auriault C., Bossus M., Deslee D., et al. Protection of mice and nude rats against toxoplasmosis by a multiple antigenic peptide construction derived from Toxoplasma gondii P30 antigen. J Immunol 1992, 149(11):3636-3641.
19. Godard I., Estaquier J., Zenner L., Bossus M., Auriault C., Darcy F., et al. Antigenicity and immunogenicity of P30-derived peptides in experimental models of toxoplasmosis. Mol Immunol 1994, 31(17):1353-1363.
20. Velge-Roussel F., Moretto M., Buzoni-Gatel D., Dimier-Poisson I., Ferrer M., Hoebeke J., et al. Differences in immunological response to a T. gondii protein (SAG1) derived peptide between two strains of mice: effect on protection in T. gondii infection. Mol Immunol 1997, 34(15):1045-1053.
21. Nielsen H.V., Lauemøller S.L., Christiansen L., Buus S., Fomsgaard A., Petersen E. Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene. Infect Immun 1999, 67(12):6358-6363.
22. Angus C.W., Klivington-Evans D., Dubey J.P., Kovacs J.A. Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents. J Infect Dis 2000, 181(1):317-324.
23. Cesbron-Delauw M.F., Lecordier L., Mercier C. Role of secretory dense granule organelles in the pathogenesis of toxoplasmosis. Curr Top Microbiol Immunol 1996, 219:59-65.
24. Murray A., Mercier C., Decoster A., Lecordier L., Capron A., Cesbron-Delauw M.F. Multiple B-cell epitopes in a recombinant GRA2 secreted antigen of Toxoplasma gondii. Appl Parasitol 1993, 34(4):235-244.
25. Mercier C., Howe D.K., Mordue D., Lingnau M., Sibley L.D. Targeted disruption of the GRA2 locus in Toxoplasma gondii decreases acute virulence in mice. Infect Immun 1998, 66(9):4176-4182.
26. Golkar M., Shokrgozar M.A., Rafati S., Musset K., Assmar M., Sadaie R., et al. Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice. Vaccine 2007, 25(21):4301-4311.
27. Zhou H., Gu Q., Zhao Q., Zhang J., Cong H., Li Y., et al. Toxoplasma gondii: expression and characterization of a recombinant protein containing SAG1 and GRA2 in Pichia pastoris. Parasitol Res 2007, 100(4):829-835.
28. Donnelly J.J., Ulme J.B., Liu M.A. Immunization with DNA. J Immunol Methods 1994, 176(2):145-152.
29. Denkers E.Y., Gazzinelli R.T. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev 1998, 11(4):569-588.
30. Munoz M., Liesenfeld O., Heimesaat M.M. Immunology of Toxoplasma gondii. Immunol Rev 2011, 240(1):269-285.
31. Tighe H., Corr M., Roman M., Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today 1998, 19(2):89-97.
32. Altin J.G., Parish C.R. Liposomal vaccines-targeting the delivery of antigen. Methods 2006, 40(1):39-52.
33. Davis H.L., Michel M.L., Whalen R.G. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet 1993, 2(11):1847-1851.
34. Woo W.P., Doan T., Herd K.A., Netter H.J., Tindle R.W. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes. J Virol 2006, 80(8):3975-3984.
35. Haigh O., Guo H., Edgtton K., Mather M., Herd K.A., Tindle R.W. Multiple copies of a tumor epitope in a recombinant hepatitis B surface antigen (HBsAg) vaccine enhance CTL responses, but not tumor protection. Virology 2007, 368(2):363-375.
36. Beláková J., Horynová M., Krupka M., Weigl E., Raska M. DNA vaccines: are they still just a powerful tool for the future?. Arch Immunol Ther Exp 2007, 55(6):387-398.
37. Oran A.E., Robinson H.L. DNA vaccines: combining form of antigen and method of delivery to raise a spectrum of IFN-gamma and IL-4-producing CD4+ and CD8+ T cells. J Immunol 2003, 171(4):1999-2005.
38. Liu M.A. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011, 239(1):62-84.
39. Perrie Y., McNeil S., Vangala A. Liposome-mediated DNA immunisation via the subcutaneous route. J Drug Target 2003, 11(8-10):555-563.
40. Sasaki S., Takeshita F., Xin K.Q., Ishii N., Okuda K. Adjuvant formulations and delivery systems for DNA vaccines. Methods 2003, 31(3):243-254.
41. Shkreta L., Talbot B.G., Lacasse P. Optimization of DNA vaccination immune responses in dairy cows: effect of injection site and the targeting efficacy of antigen-bCTLA-4 complex. Vaccine 2003, 21(19-20):2372-2382.
42. El-Malky M., Shaohong L., Kumagai T., Yabu Y., Noureldin M.S., Saudy N., et al. Protective effect of vaccination with Toxoplasma lysate antigen and CpG as an adjuvant against Toxoplasma gondii in susceptible C57BL/6 mice. Microbiol Immunol 2005, 49(7):639-646.
43. von Brunn A., Früh K., Müller H.M., Zentgraf H.W., Bujard H. Epitopes of the human malaria parasite P. falciparum carried on the surface of HBsAg particles elicit an immune response against the parasite. Vaccine 1991, 9(7):477-484.
44. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997, 336(2):86-91.
45. Regules J.A., Cummings J.F., Ockenhouse C.F. The RTS,S vaccine candidate for malaria. Expert Rev Vaccines 2011, 10(5):589-599.
46. Bryder K., Sbai H., Nielsen H.V., Corbet S., Nielsen C., Whalen R.G., et al. Improved immunogenicity of HIV-1 epitopes in HBsAg chimeric DNA vaccine plasmids by structural mutations of HBsAg. DNA Cell Biol 1999, 18(3):219-225.
47. Milich D.R. T- and B-cell recognition of hepatitis B viral antigens. Immunol Today 1988, 9(12):380-386.
48. Greenstein J.L., Schad V.C., Goodwin W.H., Brauer A.B., Bollinger B.K., Chin R.D., et al. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120. J Immunol 1992, 148(12):3970-3977.
49. Arai R., Ueda H., Kitayama A., Kamiya N., Nagamune T. Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng 2001, 14(8):529-532.
50. Gokhale R.S., Khosla C. Role of linkers in communication between protein modules. Curr Opin Chem Biol 2000, 4(1):22-27.
51. Kang H., Remington J.S., Suzuki Y. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma: TNF-alpha, and inducible nitric oxide synthase. J Immunol 2000, 164(5):2629-2634.
52. Sibley L.D., Adams L.B., Krahenbuhl J.L. Macrophage interactions in toxoplasmosis. Res Immunol 1993, 144(1):38-40.
53. Suzuki Y., Joh K., Orellana M.A., Conley F.K., Remington J.S. A gene(s) within the H-2D region determines the development of toxoplasmic encephalitis in mice. Immunology 1991, 74(4):732-739.